- Home
- TMDX
as 07-26-2024 4:00pm EST
TransMedics Group Inc is a commercial-stage medical technology company transforming organ transplant therapy for end-stage organ failure patients across multiple disease states. It has developed the Organ Care System(OCS) to comprehensively address the limitations of cold storage. The OCS is a portable organ perfusion, optimization and monitoring system that utilizes technology to replicate near-physiologic conditions for donor organs outside of the human body. The Company has developed and is commercializing a proprietary system to preserve and deliver human organs for transplant in a near-physiologic condition to address the limitations of cold storage organ preservation.
Upcoming Earnings Alert:
Get ready for potential market movements as TransMedics Group Inc. TMDX prepares to release earnings report on 01 Aug 2024.
| Founded: | 1998 | Country: | United States |
| Employees: | N/A | City: | ANDOVER |
| Market Cap: | 4.6B | IPO Year: | 2019 |
| Target Price: | $128.75 | AVG Volume (30 days): | 586.3K |
| Analyst Decision: | Buy | Number of Analysts: | 8 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -0.34 | EPS Growth: | N/A |
| 52 Week Low/High: | $36.42 - $156.05 | Next Earning Date: | 08-01-2024 |
| Revenue: | $296,919,000 | Revenue Growth: | 149.23% |
| Revenue Growth (this year): | 69.46% | Revenue Growth (next year): | 31.50% |
Stock Insider Trading Activity of TransMedics Group Inc. (TMDX)
| Name | Ticker | Relationship | Date | Transaction | Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Hassanein Waleed H | TMDX | President & CEO | Jun 14 '24 | Sell | $144.52 | 100 | $14,452.00 | 61,643 | SEC Form 4 |
| Hassanein Waleed H | TMDX | President & CEO | Jun 14 '24 | Sell | $143.65 | 400 | $57,460.00 | 61,743 | SEC Form 4 |
| Hassanein Waleed H | TMDX | President & CEO | Jun 14 '24 | Sell | $142.68 | 2,675 | $381,669.00 | 62,143 | SEC Form 4 |
| Hassanein Waleed H | TMDX | President & CEO | Jun 14 '24 | Sell | $141.62 | 3,836 | $543,254.32 | 64,818 | SEC Form 4 |
| Hassanein Waleed H | TMDX | President & CEO | Jun 14 '24 | Sell | $140.42 | 1,614 | $226,637.88 | 68,654 | SEC Form 4 |
| Basile Edward M | TMDX | Director | Jun 5 '24 | Sell | $138.08 | 1,193 | $164,729.44 | 732 | SEC Form 4 |
| Khayal Tamer I | TMDX | Chief Commercial Officer | Jun 3 '24 | Sell | $135.97 | 457 | $62,138.29 | 20,843 | SEC Form 4 |
| Khayal Tamer I | TMDX | Chief Commercial Officer | Jun 3 '24 | Sell | $134.66 | 152 | $20,468.32 | 21,300 | SEC Form 4 |
| Khayal Tamer I | TMDX | Chief Commercial Officer | Jun 3 '24 | Sell | $133.67 | 567 | $75,790.89 | 21,452 | SEC Form 4 |
| Khayal Tamer I | TMDX | Chief Commercial Officer | Jun 3 '24 | Sell | $132.71 | 921 | $122,225.91 | 22,019 | SEC Form 4 |
| Khayal Tamer I | TMDX | Chief Commercial Officer | Jun 3 '24 | Sell | $131.87 | 539 | $71,077.93 | 22,940 | SEC Form 4 |
| Khayal Tamer I | TMDX | Chief Commercial Officer | Jun 3 '24 | Sell | $130.79 | 219 | $28,643.01 | 23,479 | SEC Form 4 |
| Khayal Tamer I | TMDX | Chief Commercial Officer | Jun 3 '24 | Sell | $129.92 | 105 | $13,641.60 | 23,698 | SEC Form 4 |
| Gordon Stephen | TMDX | Chief Financial Officer | Jun 3 '24 | Sell | $135.93 | 2,060 | $280,015.80 | 21,299 | SEC Form 4 |
| Weill David | TMDX | Director | May 29 '24 | Sell | $141.65 | 1,193 | $168,988.45 | 10,732 | SEC Form 4 |
| Gordon Stephen | TMDX | Chief Financial Officer | May 29 '24 | Sell | $141.27 | 2,000 | $282,540.00 | 21,299 | SEC Form 4 |
| Gordon Stephen | TMDX | Chief Financial Officer | May 29 '24 | Sell | $141.06 | 9,345 | $1,318,205.70 | 29,954 | SEC Form 4 |
| Gordon Stephen | TMDX | Chief Financial Officer | May 29 '24 | Sell | $141.80 | 8,655 | $1,227,279.00 | 21,299 | SEC Form 4 |
| Hassanein Waleed H | TMDX | President & CEO | May 15 '24 | Sell | $133.42 | 300 | $40,026.00 | 69,968 | SEC Form 4 |
| Hassanein Waleed H | TMDX | President & CEO | May 15 '24 | Sell | $134.69 | 2,100 | $282,849.00 | 67,868 | SEC Form 4 |
| Hassanein Waleed H | TMDX | President & CEO | May 15 '24 | Sell | $135.54 | 5,481 | $742,894.74 | 62,387 | SEC Form 4 |
| Hassanein Waleed H | TMDX | President & CEO | May 15 '24 | Sell | $136.26 | 744 | $101,377.44 | 61,643 | SEC Form 4 |
| Weill David | TMDX | Director | May 10 '24 | Sell | $129.82 | 2,500 | $324,550.00 | 11,193 | SEC Form 4 |
| Basile Edward M | TMDX | Director | May 7 '24 | Sell | $128.43 | 2,130 | $273,555.90 | 6,220 | SEC Form 4 |
| Basile Edward M | TMDX | Director | May 7 '24 | Sell | $129.80 | 2,226 | $288,934.80 | 3,994 | SEC Form 4 |
Latest TransMedics Group Inc. News
TMDX Breaking Stock News: Dive into TMDX Ticker-Specific Updates for Smart Investing
Zacks
2 days ago
Is Hims & Hers Health (HIMS) Stock Outpacing Its Medical Peers This Year?
PR Newswire
8 days ago
TransMedics Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
MT Newswires
9 days ago
Transmedics Group Insider Sold Shares Worth $1,252,051, According to a Recent SEC Filing
PR Newswire
9 days ago
TransMedics to Report Second Quarter 2024 Financial Results on July 31, 2024
Zacks
10 days ago
TransMedics (TMDX) Moves to Buy: Rationale Behind the Upgrade
MT Newswires
11 days ago
Piper Sandler Adjusts TransMedics Group's PT to $170 From $120, Keeps Overweight Rating
MT Newswires
12 days ago
Morgan Stanley Boosts Price Target on TransMedics Group to $145 From $104, Keeps Equalweight Rating
Insider Monkey
13 days ago
TransMedics (TMDX) Rallied 104% in Q2
Compare TMDX vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "TMDX TransMedics Group Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.